Home
Industry Sessions
Visit the Booth
Medscape CME Session
Take Home Trial
Abstracts & Oral Presentations 

Dexcom Product Theater

Illuminating Dexcom Innovations Across the Metabolic Continuum:
Stelo supporting health behavior change and Dexcom G7 15 Day with Smart Basal

Saturday, June 6, 2026 | 12:30 – 1:30 PM | Product Theater #1 

The increasing prevalence of metabolic dysfunction and prediabetes highlights the need for earlier, more personalized approaches to care. In this presentation, experts will discuss how early CGM use with Stelo can empower individuals with metabolic health concerns and prediabetes by making glucose patterns visible and actionable, facilitating meaningful behavior change. The clinical value of introducing CGM early in metabolic health will be examined, with a focus on how real-time glucose insights can improve engagement and support healthy habits.

Expanding through the Dexcom portfolio, the presentation will then shift to focus on CGM-enabled personalization of insulin therapy. Through real-world, case-based examples, faculty will demonstrate how Dexcom Smart Basal can be used to individualize basal insulin initiation and titration by translating CGM data into actionable clinical decisions.1 This presentation will provide practical insights for clinicians seeking to integrate CGM across the continuum of care, from early metabolic risk through insulin-treated diabetes, to support individualized care and improved outcomes.
Time to Emphasize CGM Based Glycemic Optimization
Viral Shah, MD | United States
Professor of Medicine, Division of Endocrinology & Metabolism; Director of Diabetes Clinical Research, IU Center for Diabetes and Metabolic Diseases, Indiana

View Full Bio
From Metabolic Health to Prediabetes: Seeing is Believing with Stelo
Helen Baron, MD  | United States
Endocrinology, Diabetes & Metabolism Medical Director,  Diabetes Services Eisenhower Medical Center

View Full Bio
Personalized Basal Insulin Therapy Using Dexcom G7 15 Day with Smart Basal: Building a Brighter Future
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP  | United States
Endocrine Clinical Pharmacy Specialist; Director, Education & Training in Diabetes Technology; Co-Director, Endocrine Disorders in Pregnancy; Cleveland Clinic Endocrinology & Metabolism Institute; ADA 2026 Outstanding Educator in Diabetes Award

View Full Bio

Dexcom Diabetes Learning Byte

Dexcom Smart Basal: A Deeper Dive into CGM‑Guided Basal Titration 

Sunday, June 7, 2026 | 1:30 – 1:50 PM | Booth #1209  

Dexcom Smart Basal is a simple, CGM‑guided long‑acting insulin adjustment program designed to support personalized basal insulin titration in adults with type 2 diabetes. Initiated by healthcare providers in Dexcom Clarity, the program leverages Dexcom G7 15 Day CGM data, logged insulin doses, and treatment plans to generate personalized dose recommendations and deliver guided daily adjustments through the Dexcom G7 app. This session provides a deeper dive into how Dexcom Smart Basal enhances ease of use for patients while improving provider visibility into how CGM data can inform insulin titration. 
Presenter
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP  | USA
Endocrine Clinical Pharmacy Specialist; Director, Education & Training in Diabetes Technology; Co-Director, Endocrine Disorders in Pregnancy; Cleveland Clinic Endocrinology & Metabolism Institute; ADA 2026 Outstanding Educator in Diabetes Award

View Full Bio

Dexcom Innovation Hub

Innovation That Sticks: How Dexcom Built Trust, Usability, and AI‑Powered Insight 

Sunday, June 7, 2026 | 11:30 – 11:50 AM | Innovation Hub Booth #1025 

Innovation in healthcare only matters if it fits into real human lives—and lasts. This session traces Dexcom’s deliberate innovation journey, showing how long‑term leadership is built by first earning trust, seamlessly connecting data across care settings, and thoughtfully introducing intelligence that supports understanding and behavior change. Looking ahead, the session highlights what’s next in CGM‑informed care, including the intentional application of AI and enhanced insulin optimization functionality—designed to help clinicians and users identify meaningful patterns, convert continuous data into insight, and support more proactive, personalized decisions.    

Attendees will explore how innovation grounded in lived experience does more than scale—it sticks, strengthening the relationship between people, clinicians, and data so technology adapts to real life, not the other way around. 
Presenter
Keri Leone, PhD(c), MS, RD, CDCES  | USA
Senior Medical Director, Global Medical Affairs. Dexcom, San Diego, California

View Full Bio

Questions?

If you have any questions, please contact Dexcom at events@dexcom.com
*Results with Dexcom CGM have been proven in over 70 clinical studies, data available on clinicaltrials.gov. 1 Dexcom Basal Therapy Optimization User Guide, 2025. Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries.

BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. 

MAT-13836